Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Short term Debt (2018 - 2025)

Historic Short term Debt for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $3.7 billion.

  • Takeda Pharmaceutical's Short term Debt fell 499.59% to $3.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 billion, marking a year-over-year decrease of 499.59%. This contributed to the annual value of $3.6 billion for FY2025, which is 4201.79% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Short term Debt stood at $3.7 billion, which was down 499.59% from $3.7 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Short term Debt peaked at $4.5 billion during Q2 2021, and registered a low of $1.8 billion during Q1 2022.
  • Its 5-year average for Short term Debt is $3.5 billion, with a median of $3.7 billion in 2025.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Short term Debt plummeted by 5651.84% in 2021, and later surged by 4626.1% in 2023.
  • Over the past 5 years, Takeda Pharmaceutical's Short term Debt (Quarter) stood at $4.1 billion in 2021, then dropped by 12.25% to $3.6 billion in 2022, then grew by 2.9% to $3.7 billion in 2023, then rose by 6.03% to $3.9 billion in 2024, then decreased by 5.0% to $3.7 billion in 2025.
  • Its last three reported values are $3.7 billion in Q4 2025, $3.7 billion for Q3 2025, and $3.7 billion during Q2 2025.